A dermatologist guide to immunogenicity()()

Dermatologists should be aware that autoantibody formation may occur after the initiation of biologic therapy. This phenomenon has been referred to as immunogenicity and biologic fatigue. Because of this, patients may experience loss of clinical efficacy to a particular drug. To combat this phenomen...

Descripción completa

Detalles Bibliográficos
Autores principales: Blattner, Collin M., Chaudhari, Soham P., Young, John, Murase, Jenny E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418886/
https://www.ncbi.nlm.nih.gov/pubmed/28492015
http://dx.doi.org/10.1016/j.ijwd.2016.05.001
Descripción
Sumario:Dermatologists should be aware that autoantibody formation may occur after the initiation of biologic therapy. This phenomenon has been referred to as immunogenicity and biologic fatigue. Because of this, patients may experience loss of clinical efficacy to a particular drug. To combat this phenomenon, low-dose immunomodulators may be used in hopes of preventing autoantibodies. We review the current literature and provide a basic treatment algorithm for patients with moderate to severe psoriasis.

Ejemplares similares